DCM
LSTA icon

DAFNA Capital Management’s Lisata Therapeutics LSTA Stock Holding History

DAFNA Capital Management’s Portfolio LSTA Stock Details LSTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-593
Closed -$166K – 90
2015
Q2 		$166K Buy
+593
New +$220K 0.14% 68

Other funds holding LSTA

GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

DAFNA Capital Management's LSTA Position: Q3 2015 in Review

DAFNA Capital Management sold out of Lisata Therapeutics (LSTA) in Q3 2015, closing a stake of 593 shares — an estimated $166K sold.

DAFNA Capital Management first reported a position in LSTA in Q2 2015 and held it in 1 quarter. The position peaked at $166K in Q2 2015. 43 funds tracked by Wall St. Rank hold LSTA as of Q3 2015.

  • DAFNA Capital Management reported no remaining Lisata Therapeutics position as of Q3 2015 after selling out during the quarter.
  • DAFNA Capital Management sold 593 Lisata Therapeutics shares in Q3 2015, an estimated $166K.
  • DAFNA Capital Management first reported a position in Lisata Therapeutics in Q2 2015 and held it in 1 quarter.
  • DAFNA Capital Management's Lisata Therapeutics position peaked at $166K in Q2 2015.
  • 43 funds tracked by Wall St. Rank held Lisata Therapeutics as of Q3 2015.

Based on DAFNA Capital Management's 13F filing for Q3 2015, filed 13 Nov 2015.